Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 5/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.41 |
| ▸ | ESR1 | P03372 | 2/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.38 |
| ▸ | DHODH | Q02127 | 2/20 | 0.37 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 6/20 | 0.34 |
| ▸ | FEN1 | P39748 | 6/20 | 0.34 |
| ▸ | ACACA | Q13085 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26075310 | 0.90 | DHODH (0.42) | S1PR1S1PR3ESR1ESR2DHODH | |
| SCHEMBL26075395 | 0.86 | ACP1 (0.39) | S1PR1S1PR3ESR1ESR2DHODH | |
| SCHEMBL26075889 | 0.85 | ESR1 (0.38) | S1PR1S1PR3ESR1ESR2DHODH | |
| SCHEMBL26075901 | 0.84 | ESR1 (0.36) | ESR1ESR2ALOX5APFEN1PDE3B | |
| SCHEMBL26075890 | 0.83 | ESR1 (0.38) | S1PR1S1PR3ESR1ESR2DHODH | |
| SCHEMBL26075875 | 0.82 | PDE10A (0.44) | ALOX5APFEN1PDE3A | |
| SCHEMBL26075396 | 0.80 | DHODH (0.44) | S1PR1S1PR3ESR1ESR2DHODH | |
| SCHEMBL26075891 | 0.79 | DHODH (0.44) | ESR1ESR2DHODHFEN1ACACA | |
| SCHEMBL26075865 | 0.79 | ACACA (0.46) | ACACA | |
| SCHEMBL26074087 | 0.79 | DHODH (0.47) | DHODHACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303710-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | OHIO STATE INNOVATION FOUNDATION (US) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303710-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | DHODH, CD38, DPYD | S1PR1 1996/4885S1PR3 2218/4885ESR1 4427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.